On Tuesday, Shares of Synthetic Biologics Inc (NYSEMKT:SYN), gained 1.40% to $2.90.
Synthetic Biologics, declared positive topline results from the first Phase 2a study of SYN-004, the Company’s candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Topline results from the ten ileostomized participants who accomplished the Phase 2a open-label study demonstrated that SYN-004 successfully degraded residual IV ceftriaxone in the chyme (digestive fluid in the small intestine) without affecting the intended level of ceftriaxone in the bloodstream.
Evaluation of the chyme from the ileostomized participants indicates that both dosage strengths of SYN-004 (75 mg and 150 mg) degrade residual IV ceftriaxone present in the chyme, supporting the mechanism of action of SYN-004. In addition, both dosage strengths of SYN-004 appear to be well tolerated by the participants in the study. Overall, the topline data support the hypothesis that SYN-004 has the capacity to degrade residual IV ceftriaxone in the GI tract, thereby preserving the balance of the gut microbiome for the prevention of CDI, AAD and emergence of antibiotic-resistant organisms, without affecting the antibiotic level in the bloodstream intended for treatment of a primary infection.
“The completion of the first Phase 2a clinical trial for SYN-004 is an important achievement for Synthetic Biologics. These positive topline results demonstrate the potential for SYN-004 to protect the gut microbiome from the damaging effects of certain IV beta-lactam antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea,” stated Jeffrey Riley, President and Chief Executive Officer of Synthetic Biologics. “The second Phase 2a clinical trial for SYN-004 is presently ongoing to evaluate the GI antibiotic-degrading effects and the safety of SYN-004 in the presence of the proton pump inhibitor (PPI), esomeprazole, in participants with functioning ileostomies. We anticipate reporting topline results from the second Phase 2a of SYN-004 during the first half of 2016.”
Synthetics Biologics, Inc., a clinical-stage biotechnology company, develops pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection; an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C); and a monoclonal antibody combination for the treatment of Pertussis.
Shares of International Business Machines Corp. (NYSE:IBM), inclined 1.36% to $141.31, during its last trading session.
International Business Machines Corp., declared that Manipal Hospitals’ corporate and teaching facilities will adopt Watson for Oncology, a cognitive computing platform trained by Memorial Sloan-Kettering that analyzes data to identify evidence-based treatment options, assisting oncologists to provide cancer patients with individualized healthcare. More than 200,000 individuals receive care for cancer at Manipal facilities each year. This will be the first deployment of Watson in India and the first engagement of its kind as the country advances efforts to transform healthcare.
Watson represents a fundamental shift in the paradigm of computing – moving from programmable systems which have been the mainstay for the last several decades to learning systems that keep getting smarter as they process more knowledge. Based on cutting-edge research led by IBM computer scientists, Watson has the ability to read and understand natural language. Watson for Oncology was developed by IBM in concert with Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading cancer centers. To date, Watson for Oncology has ingested nearly 15 million pages of medical content, counting more than 200 medical textbooks and 300 medical journals.
International Business Machines Corporation provides information technology (IT) products and services worldwide. The company’s Global Technology Services segment provides IT infrastructure and business process services, such as outsourcing, processing, integrated technology, cloud, and technology support.
Finally, Shares of Qorvo Inc (NASDAQ:QRVO), ended its last trade with -0.05% loss, and closed at $58.04.
Qorvo, declared that Company executives are planned to present at three forthcoming investor conferences:
- Credit Suisse 19th Annual Technology, Media & Telecom Conference, Thursday, December 3, 2015, in Scottsdale, AZ., at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time)
- Barclays Global Technology, Media and Telecommunications Conference, Tuesday, December 8, 2015, in San Francisco, CA, at 8:25 a.m. Pacific Time (11:25 a.m. Eastern Time)
- Raymond James Technology Investors Conference, Wednesday, December 9, 2015, in New York, NY, at 9:00 a.m. Eastern Time
Qorvo, Inc. provides technologies and radio frequency (RF) solutions for mobile, infrastructure, defense, and aerospace applications in the United States and internationally. The company operates through Mobile Products, and Infrastructure and Defense Products segments.